C90.0
Conditions
Interventions
Group 1: RRMM patients, who have received at least one therapy for MM and for whom myeloablative conditioning and stem-cell transplantation was planned in the second or third therapy line
Sponsors
AMGEN (Europe) GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Patient aged 18 years or older at index date* - Patient with diagnosis of MM histologically or cytologically confirmed as defined according to IMWG - Patient had already received at least one therapy for MM and then relapsed or was refractory to initial therapy after initial response - Patient was planned to receive myeloablative conditioning and SCT in second or third line based on assessment at index date* - Start date of (re-)induction therapy (index date*) was within the period from January 2016 to December 2019 - Patient had completed a (re-)induction therapy in second or third line (index therapy) *Index date is defined as start of (re-)induction therapy for a planned myeloablative conditioning and SCT in second or third line.
Exclusion criteria
Exclusion criteria: - Patient not eligible for SCT based on physician’s assessment prior to start of (re )induction therapy in second or third line. - Patient did not complete (re-)induction therapy in second or third line.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - To describe patient characteristics - To describe treatment patterns (previous treatments, current treatment, maintenance therapy) of RRMM patients who have received (re-)induction therapy for a planned myeloablative conditioning and SCT in second or third line. | — |
Secondary
| Measure | Time frame |
|---|---|
| - The percentage of RRMM patients transplanted after receiving (re-)induction therapy in second or third line - The type of SCT (autologous or allogeneic) - Different times to next treatment - Duration of remission Exploratory objectives: - Progression free survival (PFS) - Overall survival (OS) - Minimal residual disease (MRD) testing pattern | — |
Countries
Germany
Contacts
Public ContactSandra Sauer
Universitätsklinikum Heidelberg
Outcome results
None listed